2,787 results match your criteria Sentinel Lymph Node Biopsy in Patients With Melanoma


Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours.

Eur J Cancer 2021 Jul 20;154:227-234. Epub 2021 Jul 20.

Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany; Department of Dermatology, University Hospital (UKSH), Kiel, Germany.

Aim: Sentinel lymph node status is a central prognostic factor for melanomas. However, the surgical excision involves some risks for affected patients. In this study, we therefore aimed to develop a digital biomarker that can predict lymph node metastasis non-invasively from digitised H&E slides of primary melanoma tumours. Read More

View Article and Full-Text PDF

Compliance with sentinel lymph node biopsy guidelines for invasive melanomas treated with Mohs micrographic surgery.

Cancer 2021 Jul 22. Epub 2021 Jul 22.

Department of Dermatology, University of Pennsylvania Health System, Philadelphia, Pennsylvania.

Background: Sentinel lymph node biopsy (SLNB) has not been studied for invasive melanomas treated with Mohs micrographic surgery using frozen-section MART-1 immunohistochemical stains (MMS-IHC). The primary objective of this study was to assess the accuracy and compliance with National Comprehensive Cancer Network (NCCN) guidelines for SLNB in a cohort of patients who had invasive melanoma treated with MMS-IHC.

Methods: This retrospective cohort study included all patients who had primary, invasive, cutaneous melanomas treated with MMS-IHC at a single academic center between March 2006 and April 2018. Read More

View Article and Full-Text PDF

Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy.

Ann Surg Oncol 2021 Jul 17. Epub 2021 Jul 17.

Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA.

Background: Randomized clinical trials support deescalation of axillary surgery in breast cancer patients with low-volume axillary disease treated with a surgery-first approach. However, few data exist to guide axillary surgery following neoadjuvant endocrine therapy (NET). Therefore, we evaluated the extent and outcomes of axillary surgery in a contemporary cohort of NET patients, a treatment approach that has become particularly relevant during the coronavirus disease-19 (COVID-19) pandemic. Read More

View Article and Full-Text PDF

Impact of multiple lymphatic basin drainage in truncal melanoma patients.

J Plast Reconstr Aesthet Surg 2021 Jun 18. Epub 2021 Jun 18.

Internal Medicine Clinic, University Clinical Centre of the Republic of Srpska, 12 Beba bb Street, Banja Luka, Republic of Srpska 78 000, Bosnia and Herzegovina.

Introduction: In many patients with cutaneous melanoma that affects the trunk area, there is lymphatic drainage to multiple basins (MLBD). This study aimed to examine whether MLBD is associated with disease outcomes.

Methods: Lymphatic mapping and sentinel lymph node (SLN) biopsy were performed in 161 patients with truncal melanoma. Read More

View Article and Full-Text PDF

Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study.

Eur J Cancer 2021 Jul 10;154:111-119. Epub 2021 Jul 10.

Netherlands Comprehensive Cancer Organisation, Godebaldkwartier 419, 3511 DT, Utrecht, the Netherlands.

Objective: To examine stage-specific trends in the incidence and survival of cutaneous melanoma in the Netherlands between 2003 and 2018, as well as the uptake of the sentinel lymph node biopsy (SLNB) and novel drugs during that period.

Methods: Data were obtained from the nationwide population-based Netherlands Cancer Registry for all patients diagnosed with invasive primary cutaneous melanoma (n = 60,267). We presented age-standardized incidence rates, the proportion of patients with an SLNB, the proportion of patients who received a novel drug (for their primary diagnosis) and one- and five-year relative survival rates. Read More

View Article and Full-Text PDF

Histological regression in melanoma: impact on sentinel lymph node status and survival.

Mod Pathol 2021 Jul 10. Epub 2021 Jul 10.

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Regression in melanoma is an immunological phenomenon that results in partial or complete replacement of the tumor with variably vascular fibrous tissue, often accompanied by pigment-laden macrophages and chronic inflammation. In some cases, tumor-infiltrating lymphocytes (TILs) may represent the earliest phase of this process. The prognostic significance of regression has long been a matter of debate, with inconsistent findings reported in the literature to date. Read More

View Article and Full-Text PDF

Elective management of regional nodal basins in cutaneous squamous cell carcinoma of the head and neck: Controversies and contemporary perspectives.

Oral Oncol 2021 Jul 2;120:105432. Epub 2021 Jul 2.

Liverpool Head and Neck Centre, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, United Kingdom.

Non-melanoma skin cancer (NMSC) is among the most common cancers worldwide, with an incidence that continues to rise. Although cutaneous squamous cell carcinoma (cSCC) constitutes only approximately 20% of such cases, it represents the most common cause of NMSC mortality, owing largely to the propensity for development of regional lymph node metastases (LNM), which, when present, carry a dismal prognosis. Whilst overall rates of LNM are low, there are a number of patient and tumour factors that likely confer considerably higher risks, which has led several investigators to propose more proactive elective management of regional nodal basins in selected high-risk cases. Read More

View Article and Full-Text PDF

Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma-A Retrospective Single-Institute Study.

Cancers (Basel) 2021 Jun 30;13(13). Epub 2021 Jun 30.

National Cancer Registry, National Institute of Oncology, 1122 Budapest, Hungary.

Purpose: To assess the prognostic role of sentinel lymph node status (SLN) in melanoma patients, a statistical comparison was performed with the application of already known prognostic factors, mutational occurrence of BRAF and NRAS in the primary tumor, as well as disease outcome.

Methods: Our retrospective single-center study involved 159 melanoma cases, who underwent SLN biopsy. The following clinico-pathological data were collected: age, gender, location of primary tumor, Breslow thickness, ulceration degree, histological subtype, mitosis count, lymphovascular and perineural invasion, presence of tumor-infiltrating lymphocytes, regression signs, mutations of BRAF and NRAS of the primary tumors, and SLN status. Read More

View Article and Full-Text PDF

Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.

Int J Mol Sci 2021 Jun 11;22(12). Epub 2021 Jun 11.

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.

Merkel cell carcinoma (MCC) is an uncommon and highly aggressive skin cancer. It develops mostly within chronically sun-exposed areas of the skin. MCPyV is detected in 60-80% of MCC cases as integrated within the genome and is considered a major risk factor for MCC. Read More

View Article and Full-Text PDF

Indocyanine Green Fluorescence Imaging with Lymphoscintigraphy Improves the Accuracy of Sentinel Lymph Node Biopsy in Melanoma.

Plast Reconstr Surg 2021 Jul;148(1):83e-93e

From the Department of Plastic Surgery, Cleveland Clinic.

Background: Despite advances in melanoma management, there remains room for improvement in the accuracy of sentinel lymph node biopsy. The authors analyzed a prospective cohort of patients with primary cutaneous melanoma who underwent sentinel lymph node biopsy with lymphoscintigraphy and indocyanine green fluorescence to evaluate the quality and accuracy of this technique.

Methods: Consecutive primary cutaneous melanoma patients who underwent sentinel lymph node biopsy with radioisotope lymphoscintigraphy and indocyanine green fluorescence from 2012 to 2018 were prospectively enrolled. Read More

View Article and Full-Text PDF

The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma.

Mod Pathol 2021 Jun 15. Epub 2021 Jun 15.

Institute of Pathology, University Medical Center, Göttingen, Germany.

Sentinel lymph node (SN) tumor burden is becoming increasingly important and is likely to be included in future N classifications in melanoma. Our aim was to investigate the prognostic significance of melanoma infiltration of various anatomically defined lymph node substructures. This retrospective cohort study included 1250 consecutive patients with SN biopsy. Read More

View Article and Full-Text PDF

Sentinel lymph node biopsy guideline concordance in melanoma: Analysis of the National Cancer Database.

J Surg Oncol 2021 Jun 9. Epub 2021 Jun 9.

University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

Background And Objectives: This study investigated the impact of treating facility type on guideline-concordant sentinel lymph node biopsy (SLNB) management in T1a* (defined as a Breslow depth <0.76 mm without ulceration or mitoses) and T2/T3 melanoma.

Methods: This was a retrospective cohort study utilizing the National Cancer Database from 2012 to 2016. Read More

View Article and Full-Text PDF

Sentinel lymph node biopsy in melanoma: beyond histologic factors.

Clin Exp Metastasis 2021 Jun 8. Epub 2021 Jun 8.

Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.

Sentinel lymph node (SLN) biopsy should be performed with the technical expertise required to correctly identify the sentinel node, in the context of understanding both the likelihood of positivity in a given patient and the prognostic significance of a positive or negative result. National Comprehensive Cancer Network guidelines recommend SLN biopsy for all cutaneous melanoma patients with primary tumor thickness greater than 1 mm and in select patients with thickness between 0.8 and 1 mm, yet admit a lack of consistent clarity in its utility for prognosis and therapeutic value in tumors < 1 mm and leave the decision for undergoing the procedure up to the patient and treating physician. Read More

View Article and Full-Text PDF

Obesity is not associated with disease-free interval, melanoma-specific survival, or overall survival in patients with clinical stage IB-II melanoma after SLNB.

J Surg Oncol 2021 Jun 4. Epub 2021 Jun 4.

Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Background And Objectives: Clinicopathologic characteristics have prognostic value in clinical stage IB-II patients with melanoma. Little is known about the prognostic value of obesity that has been associated with an increased risk for several cancer types and worsened prognosis after diagnosis. This study aims to examine effects of obesity on outcome in patients with clinical stage IB-II melanoma. Read More

View Article and Full-Text PDF

Assessment of Frailty Can Guide Decision Making for Utilization of Sentinel Lymph Node Biopsy in Patients with Thick Melanoma.

Ann Surg Oncol 2021 Jun 3. Epub 2021 Jun 3.

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: Sentinel lymph node biopsy (SLNB) is often omitted in selected patients with advanced primary melanoma, although the justification/criteria for omission have been debated.

Objective: We sought to determine whether assessment of frailty could serve as an objective marker to guide selection for SLNB in patients with advanced primary melanoma.

Methods: Patients presenting with clinical stage IIC (ulcerated, > 4 mm Breslow thickness) cutaneous melanoma from January 1999 through June 2019 were included. Read More

View Article and Full-Text PDF

Near-Infrared Fluorescence Imaging for Sentinel Lymph Node Identification in Melanoma Surgery.

Cureus 2021 Apr 18;13(4):e14550. Epub 2021 Apr 18.

Plastic and Reconstructive Surgery, Cleveland Clinic Florida, Weston, USA.

Although less common than other types of skin cancers, melanoma is accountable for the majority of skin cancer-related deaths. The standard management for patients with clinically negative nodes includes a sentinel lymph node (SLN) biopsy, which is commonly performed using a combination of radioactive tracer (Tc-99) and a blue dye (isosulfan or patent blue). There are numerous drawbacks associated with Tc-99 and blue dyes such as elevated costs, logistical challenges, and anaphylactic reactions among others. Read More

View Article and Full-Text PDF

Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics.

Am J Obstet Gynecol 2021 May 29. Epub 2021 May 29.

Division of Gynaecologic Oncology, Department of Obstetrics and Gynecology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Objective: A sentinel lymph node biopsy is widely accepted as the standard of care for surgical staging in low-grade endometrial cancer, but its value in high-grade endometrial cancer remains controversial. The aim of this systematic review and meta-analysis was to evaluate the performance characteristics of sentinel lymph node biopsy in patients with endometrial cancer with high-grade histology (registered in the International Prospective Register of Systematic Reviews with identifying number CRD42020160280).

Data Sources: We systematically searched the MEDLINE, Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Embase databases all through the OvidSP platform. Read More

View Article and Full-Text PDF

The Role of Clinical Prediction Tools to Risk Stratify Patients with Melanoma After a Positive Sentinel Lymph Node Biopsy.

Authors:
Michael E Egger

Ann Surg Oncol 2021 Aug 28;28(8):4082-4083. Epub 2021 May 28.

Hiram C. Polk Jr., M.D. Department of Surgery, University of Louisville, Louisville, KY, USA.

View Article and Full-Text PDF

PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review.

Melanoma Res 2021 08;31(4):397-401

Department of Plastic Surgery.

In this centre, patients with pT4b cutaneous melanoma are staged using 18F-FDG PET-computed tomography (PET-CT) prior to considering sentinel lymph node biopsy (SLNB). The objective was to assess the utility of PET-CT in terms of rates of detection of metastases leading to changes in planned treatment and if performing PET-CT was associated with a delay in surgical management. In this single-centre retrospective cohort study, 88 consecutive patients with pT4b melanoma were identified from February 2014 to May 2019. Read More

View Article and Full-Text PDF

Survival of sentinel node biopsy versus observation in intermediate-thickness melanoma: A Dutch population-based study.

PLoS One 2021 25;16(5):e0252021. Epub 2021 May 25.

Netherlands Comprehensive Cancer Organization, IKNL, Utrecht, The Netherlands.

Background: The Multicenter Selective Lymphadenectomy Trial (MSLT-1) comparing survival after a sentinel lymph node biopsy (SLNB) versus nodal observation in melanoma patients did not show a significant benefit favoring SLNB. However, in subgroup analyses melanoma-specific survival among patients with nodal metastases seemed better.

Aim: To evaluate the association of performing a SLNB with overall survival in intermediate thickness melanoma patients in a Dutch population-based daily clinical setting. Read More

View Article and Full-Text PDF

The Importance of SPECT/CT in Preoperative Localization of Sentinel Lymph Nodes in 2 Patients With Acral Melanoma in the Foot.

Clin Nucl Med 2021 May 12. Epub 2021 May 12.

From the Departments of Dermatology Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine; and Departments of General Surgery Orthopedics, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People's Republic of China.

Abstract: A 68-year-old woman with melanoma in the left heel underwent sentinel node lymphoscintigraphy and radioguided biopsy. The sentinel node lymphoscintigraphy with SPECT/CT detected 3 foci of increased activity in the popliteal fossa and inguinal region. When coregistered to CT, the sentinel node was localized in the inguinal region, and the popliteal foci were considered tracer retention in lymphatic vessel. Read More

View Article and Full-Text PDF

Local and regional therapy for primary and locally recurrent melanoma.

Clin Adv Hematol Oncol 2021 Apr;19(4):246-260

Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.

In the vast majority of cases, cutaneous melanoma presents as localized disease and is treated with wide excision and sentinel lymph node biopsy, with shared decision making regarding completion lymph node dissection and adjuvant systemic therapy. The treatment of recurrent and in-transit disease is more complex, with further options for regional and systemic therapies and multiple variables to be factored into decisions. Rates of overall and complete response to regional therapies can be quite high in carefully chosen patients, which limits the need for systemic therapies and their inherent side effects. Read More

View Article and Full-Text PDF

Sentinel node tumor burden in cutaneous melanoma. Survival with competing risk analysis and influence in relapses and non-sentinel node status: retrospective cohort study with long follow-up in a Spanish population.

Arch Dermatol Res 2021 May 10. Epub 2021 May 10.

Dermatology Department of Complejo Hospitalario de Navarra, C/Irunlarrea., 31008, Pamplona, Navarra, Spain.

Several authors have studied the potential of sentinel lymph node (SLN) tumor burden as prognostic factor but the microscopic classifications used in different study groups were variable. We examined the prognostic role of tumor burden in SLN on melanoma specific-survival and competing causes of death. We also analysed clinical and histological factors as predictors of disease relapses and additional non sentinel lymph node (NSLN) metastases. Read More

View Article and Full-Text PDF

Current management of melanoma patients with nodal metastases.

Clin Exp Metastasis 2021 May 7. Epub 2021 May 7.

Department of Surgery, Morsani School of Medicine, University of South Florida, Tampa, FL, USA.

The management of melanoma patients with nodal metastases has undergone dramatic changes over the last decade. In the past, the standard of care for patients with a positive sentinel lymph node biopsy (SLNB) was a completion lymph node dissection (CLND), while patients with palpable macroscopic nodal disease underwent a therapeutic lymphadenectomy in cases with no evidence of systemic spread. However, studies have shown that SLN metastases present as a spectrum of disease, with certain SLN-based factors being prognostic of and correlated with outcomes. Read More

View Article and Full-Text PDF

Observation policy for sentinel node metastasis of melanoma: Comparative study with completion lymph node dissection in Japanese patients.

J Dermatol 2021 Aug 7;48(8):1221-1228. Epub 2021 May 7.

Division of Dermatology, Niigata Cancer Center Hospital, Niigata, Japan.

Based on the results of international multicenter randomized trials, completion lymph node dissection for patients with sentinel lymph node-positive melanoma is no longer routinely recommended. However, clinicians should take into consideration racial and medical resource differences when applying this evidence to clinical practice in Japan. To evaluate the clinical validity of the observation policy of omitting completion lymph node dissection, we retrospectively surveyed patients with sentinel lymph node-positive melanoma between 2002 and 2020 at Niigata Cancer Center Hospital. Read More

View Article and Full-Text PDF

Proposed quality performance indicators of sentinel lymph node biopsy for cutaneous melanoma.

ANZ J Surg 2021 May 6. Epub 2021 May 6.

Department of Cutaneous Oncology, North Shore Hospital, Waitematā District Health Board, Auckland, New Zealand.

Background: Melanoma is a leading cause of morbidity and mortality in Australia and New Zealand. New Zealand has the highest melanoma incidence in the world alongside Australia at 54 per 100 000 persons. The aim of this study is to conduct a retrospective quality audit of sentinel lymph nodal biopsy (SLNB) practices from 2007 to 2019 of a high-volume melanoma surgeon. Read More

View Article and Full-Text PDF

Volar location and degree of pigmentation are associated with poor survival and first metastasis pattern in acral melanoma.

Pigment Cell Melanoma Res 2021 May 2. Epub 2021 May 2.

Departments of Dermatology, Chonnam National University Medical School, Gwangju, Korea.

The risk factors affecting acral melanoma metastasis and prognosis remain unclear. The study included 168 patients with invasive acral melanoma who were followed for ≥3 years. We evaluated patient demographics, stages, clinicopathological features, anatomic site of melanoma including nail versus volar surface, and degree of melanoma pigmentations, sentinel lymph node biopsy results, and the first metastasis sites. Read More

View Article and Full-Text PDF

How we treat locoregional melanoma.

ESMO Open 2021 Jun 27;6(3):100136. Epub 2021 Apr 27.

Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale dei Tumori IRCCS Fondazione Pascale, Napoli, Italy. Electronic address:

Cutaneous melanoma is the most lethal form of skin cancer and its incidence has been increasing in the past 30 years. Although this is completely resectable in most cases, thicker melanoma and those with regional lymph-node involvement are at a high risk of relapse. In recent years, the management of locoregional disease has drastically changed. Read More

View Article and Full-Text PDF

Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.

Int J Dermatol 2021 Jul 29;60(7):851-856. Epub 2021 Apr 29.

Mayo Clinic, Rochester, MN, USA.

Background: Approximately 85% of melanoma patients who undergo a sentinel lymph node biopsy (SLNB) are node-negative. Melanoma incidence is highest in patients ≥65 years, but their SLNB positivity rate is lower than in younger patients. CP-GEP, a model combining clinicopathologic and gene expression variables, identifies primary cutaneous melanoma (CM) patients who may safely forgo SLNB due to their low risk for nodal metastasis. Read More

View Article and Full-Text PDF